NVO — Novo Nordisk A/S Share News
0.000.00%
Last trade - 00:00- $175.03bn
- $189.31bn
- DKK309.06bn
Jiangsu Hengrui rises on licensing deal with Novo Nordisk for obesity drug
China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
Brief: Novo And Hengrui Pharma Enter Exclusive License Agreement For HRS-1596
Anthropic rolls out second Claude 5.5 model as it builds toward IPO
Mylan asks US court to clear Wegovy generic from Novo patent claims
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Brief: Nanexa And Novo Enter Global License, Collaboration Deal
Factbox: US companies face rise in cyber attacks
Novo Nordisk’s obesity feast lacks a second course
Live Markets: Before the bell: Europe higher as oil stays below $100
Denmark's central bank sees 4% GDP growth in 2026, boosted by pharmaceutical industry (updated)
Novo Nordisk open to direct New York listing, CEO Doustdar tells FT (updated)
Novo Nordisk open to New York listing upgrade, CEO Doustdar tells FT
Brief: Ozempic-Maker Novo Open To Upgrading Us Listing - Ft
Health Rounds: Wegovy pill may be best GLP-1 option to tackle recent weight gain
Novo CEO says pills could capture 50% of weight-loss market by 2030
European drugmakers call for faster trials, more spending to compete with US, China
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Novo Expands Partnership With UNICEF, Commits $18 Million